Innate Pharma to Host Q3 2025 Results and Business Update Conference Call & Webcast

11/05/2025 – 01:00 AM

MARSEILLE, France — Innate Pharma SA (IPHA), a biotechnology company specializing in immunotherapies, announced it will host a conference call on Thursday, November 13, 2025, at 2 p.m. CET / 8 a.m. ET to provide insights into its business progress during the third quarter of 2025.

The call will feature presentations and Q&A from key Innate Pharma executives:

• Jonathan Dickinson, Chief Executive Officer
• Sonia Quaratino, Executive Vice President, Chief Medical Officer
• Yannis Morel, Executive Vice President, Chief Operating Officer
• Stéphanie Cornen, Vice President, Investor Relation, Communication and Commercial Strategy
• Frédéric Lombard, Senior Vice President, Chief Financial Officer

Conference Call and Webcast Details

Interested parties can access the live webcast at: Analysts can also participate via telephone.

A replay of the webcast will be available on Innate Pharma’s website for 90 days following the event.

Innate Pharma: A Focus on Immunotherapy Innovation

Innate Pharma is positioning itself as a key player in the development of immunotherapies for cancer. The company leverages its antibody-engineering expertise to develop novel therapeutic approaches. These include monoclonal antibodies (mAbs), Antibody Drug Conjugates (ADCs), and multi-specific NK Cell Engagers utilizing its proprietary ANKET® (Antibody-based NK cell Engager Therapeutics) platform.

The company’s pipeline features several promising candidates: lacutamab, an anti-KIR3DL2 mAb targeting advanced forms of cutaneous T cell lymphomas and peripheral T cell lymphomas; IPH4502, a Nectin‑4 ADC aimed at solid tumors; and monalizumab, an anti-NKG2A antibody developed in partnership with AstraZeneca targeting non-small cell lung cancer. The monalizumab collaboration with AstraZeneca is particularly noteworthy, demonstrating Innate Pharma’s ability to partner with industry giants and validates the potential of its innovative pipeline.

Strategic partnerships form a cornerstone of Innate Pharma’s business model. Collaborations with Sanofi and AstraZeneca, alongside relationships with research institutions, are intended to drive innovation and accelerate the development of new therapies for patients. This collaborative approach allows Innate Pharma to leverage external expertise and resources, mitigating some of the risks inherent in drug development.

Financial and Strategic Outlook

Investors will be keenly focused on several key areas during the Q3 2025 update. First, progress reports on the clinical trials for lacutamab, IPH4502, and monalizumab will be critical in evaluating the near-term potential of Innate Pharma’s pipeline. Specific attention will likely be given to the rate of patient enrollment, interim efficacy data, and any reported adverse events. A deeper dive into AstraZeneca’s monalizumab plans for non-small cell lung cancer will also offer a gauge on the commercial viability of the compound and consequently, Innate Pharma’s royalty stream.

Second, the company’s cash burn rate and runway are crucial metrics, given the capital-intensive nature of biotechnology research and development. Analysts will be looking for updates on any potential financing activities, including partnerships or equity offerings, which will shape Innate Pharma’s ability to fund its pipeline development. A forward looking statement as to projected expenses will also be critical.

Third, Innate Pharma operates within a highly competitive landscape. Competitors are developing new drugs that work through alternative pathways. Therefore the market will want to confirm that Inate Pharma has a defensible competitive advantage, or that its portfolio is sufficiently differentiated, including how Innate Pharma will manage regulatory hurdles, particularly in markets outside the US and Europe.

With headquarters in Marseille, France, and a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq. The company is strategically positioned to advance its immunotherapy pipeline and contribute to the evolving landscape of cancer treatment.

Learn more about Innate Pharma at and follow them on LinkedIn and X.

Innate Pharma Shares

Forward-Looking Statements

This press release includes forward-looking statements subject to risks and uncertainties defined in securities laws, including the Private Securities Litigation Reform Act of 1995. The statements, identified by words like “anticipate,” “believe,” and “expect,” are based on reasonable assumptions but are not guarantees of future performance. Numerous risks and uncertainties could cause actual results to differ significantly. These risks and uncertainties include, but are not limited to, safety, progression of, and results from ongoing and planned clinical trials and preclinical studies; regulatory reviews and approvals; manufacturing of product candidates by third parties; commercialization efforts; and the ability to raise capital. Refer to the Risk Factors section of the Universal Registration Document (available on the AMF website) and public filings with the U.S. Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2024, for a comprehensive discussion of risks and uncertainties. Information on the Company’s website and the AMF website is for informational purposes and not incorporated by reference. Innate Pharma undertakes no obligation to update forward-looking statements unless required by law.

This press release does not constitute an offer to sell or a solicitation of an offer to buy shares in Innate Pharma in any country.